drug fast track
The Future of Biosimilars - A Case of Untapped Potential?
March 26 by Gerald ClarkeThe patents on a majority of the top-selling biologic drugs currently on the market will have expired by 2020, an amount which may be equivalent to $67 billion. Can we expect then a rush of biosimil...